KEYTRUDA® Shows Promising Results as Adjuvant Therapy for Renal Cell Carcinoma Patients
Merck's anti-PD-1 therapy, KEYTRUDA, has shown a statistically significant improvement in overall survival (OS) as adjuvant therapy for patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, according to the Phase 3 KEYNOTE-564 trial. This marks the first time a therapy has demonstrated a survival benefit compared to placebo in this patient population. The results build on the previously reported disease-free survival benefit from the same trial. KEYTRUDA's safety profile was consistent with previous studies, and the results will be presented at an upcoming medical meeting and submitted to regulatory authorities.
